Trial Profile
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Polyphenon E (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Biomarker
- 21 Jun 2012 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 15 Nov 2011 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 07 Mar 2011 Planned end date changed from 1 Jun 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.